# Selexipag (Uptravi)

Source: https://ourhealthnetwork.com/drugs/selexipag
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Selexipag?

Selexipag (brand name: Uptravi) is a prostacyclin receptor agonist. It is prescribed to treat hypertension, pulmonary. Across the United States, 794 doctors prescribe Selexipag to approximately 1,000 Medicare patients.

## Brand names

Uptravi

## Indications

Selexipag is prescribed for the treatment of hypertension and pulmonary.

## Conditions treated

- [Hypertension](https://ourhealthnetwork.com/conditions/hypertension)
- [Pulmonary](https://ourhealthnetwork.com/conditions/pulmonary)

## Mechanism of action

Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin. Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag.

## Drug classification

- Established Pharmacologic Class: Prostacyclin Receptor Agonist [EPC]
- Mechanism of Action class: Prostacyclin Receptor Agonists [MoA]
- Route of administration: ORAL

## Common side effects

anemia, arthralgia, decreased appetite, diarrhea, flushing, headache, rash, swelling

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)